Actively Recruiting
CP: Intestinal Permeability
Led by Rousselot BVBA · Updated on 2026-05-14
92
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
R
Rousselot BVBA
Lead Sponsor
A
Atlantia Food Clinical Trials
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to to evaluate the effects of 45 days daily administration of three different doses (2.5g, 5g, and 10g) of collagen peptide in healthy adults as compared to a Placebo on intestinal permeability following an acute aspirin challenge. The main question\[s\] it aims to answer Change from Day 42 to Day 45 following an acute aspirin challenge (NSAID) between three different doses (2.5g, 5g, and 10g) of collagen peptide respectively as compared to a Placebo on intestinal permeability measured by the urinary lactulose : mannitol ratio (test collected over a period of 5 hours). Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\].
CONDITIONS
Official Title
CP: Intestinal Permeability
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide written informed consent
- Aged between 18 and 65 years inclusive
- Moderate gastrointestinal symptoms with average GSRS-IBS score between 2.5 and 4.5 at screening visits
- Past aspirin use without adverse events
- Willing to avoid alcohol 2 days before each permeability test
- Willing to avoid lactulose, sugar substitutes, sucralose, or mannitol-containing products 24 hours before urine collection
- Willing to consume the study product daily during the study
You will not qualify if you...
- Pregnant, breastfeeding, or planning pregnancy during the study
- Biological childbearing potential without continuous effective contraception
- DASS-21 Depression score over 21 at screening
- History of drug or alcohol abuse exceeding national recommendations
- Food allergies or issues preventing intake of study products
- Lactose intolerance
- Vegetarian unwilling to consume animal-based supplements
- Intolerance to aspirin
- Significant acute or chronic health conditions preventing study participation or confounding results, including diagnosed gastrointestinal conditions, severe cardiovascular disease, severe kidney disease, liver disease, diabetes, or bleeding disorders
- Current or recent use of medications interfering with study, including gut motility medications, regular NSAIDs use within 2 months, or antibiotics within 4 weeks
- Current or recent use of nutritional or non-nutritional supplements interfering with study, including collagen supplements, gut motility affecting supplements, cannabidiol/hemp products, probiotics, prebiotics, or postbiotics
- Considered unlikely to comply with study or poor attendance
- Participation in other clinical studies without sufficient washout period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Atlantia Clinical Trials
Cork, Ireland, Ireland, T23 R50R
Actively Recruiting
Research Team
A
Andrea Doolan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here